Last 47 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Merck & Co., Inc.'s quarterly P/E stands at 22.1x, up 31.6% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has compressed 31.1% YoY to 8.6x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 15.60 | 22.11 | 9.04 | 11.24 | 11.16 | 16.80 | 22.90 | 14.46 | 17.64 | — | 13.84 | — | 23.96 |
| — | +31.6% | -60.5% | -22.3% | -36.7% | — | +65.5% | — | -26.4% | — | -17.7% | — | +98.6% | |
| P/S Ratio | 4.32 | 4.01 | 3.05 | 3.15 | 3.64 | 4.04 | 4.33 | 4.89 | 5.32 | 4.76 | 4.11 | 4.87 | 4.68 |
| — | -0.8% | -29.6% | -35.6% | -31.6% | -15.0% | +5.5% | +0.3% | +13.6% | -6.9% | +12.2% | +22.8% | +43.1% | |
| P/B Ratio | 5.41 | 4.97 | 4.04 | 4.05 | 4.69 | 5.45 | 6.48 | 7.22 | 8.30 | 7.40 | 6.35 | 7.56 | 5.79 |
| — | -8.8% | -37.6% | -43.8% | -43.5% | -26.3% | +2.0% | -4.6% | +43.5% | +20.5% | +29.1% | +41.5% | +13.8% | |
| P/FCF | 22.69 | 35.89 | 7.67 | 19.66 | 48.46 | 25.15 | 8.48 | 16.25 | 37.65 | — | 9.62 | 26.74 | 204.37 |
| — | +42.7% | -9.6% | +21.0% | +28.7% | — | -11.8% | -39.2% | -81.6% | — | -21.4% | +46.6% | +1383.3% | |
| EV / EBITDA | 10.79 | 8.63 | 6.82 | 7.63 | 8.11 | 12.53 | 15.09 | 11.76 | 13.51 | — | 10.47 | — | 15.24 |
| — | -31.1% | -54.8% | -35.1% | -39.9% | — | +44.2% | — | -11.4% | — | -11.0% | — | +77.6% | |
| EV / EBIT | 13.47 | 12.09 | 7.80 | 8.90 | 9.44 | 15.44 | 17.65 | 13.51 | 15.25 | — | 12.14 | — | 18.78 |
| — | -21.7% | -55.8% | -34.2% | -38.1% | — | +45.4% | — | -18.8% | — | -22.0% | — | +65.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Merck & Co., Inc.'s operating margin was 37.7% in Q4 2025, down 5.7 pp QoQ and up 9.9 pp YoY. The trailing four-quarter average of 41.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 6.6% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.0% | 70.5% | 75.6% | 75.7% | 75.1% | 75.5% | 75.5% | 76.8% | 77.6% | 73.3% | 73.3% | 73.2% | 72.9% |
| — | -6.6% | +0.1% | -1.4% | -3.1% | +3.1% | +3.0% | +4.8% | +6.4% | +1.8% | -0.6% | +3.0% | +10.2% | |
| Operating Margin | 36.2% | 37.7% | 43.4% | 40.2% | 43.0% | 27.8% | 23.9% | 38.0% | 36.5% | -11.7% | 36.8% | -33.3% | 26.3% |
| — | +35.6% | +81.6% | +5.8% | +17.7% | +337.7% | -35.0% | +214.1% | +39.0% | -146.4% | +34.0% | -196.0% | -25.7% | |
| Net Margin | 28.1% | 18.2% | 33.7% | 28.0% | 32.5% | 24.0% | 19.0% | 33.9% | 30.2% | -8.4% | 29.7% | -39.7% | 19.5% |
| — | -24.2% | +77.6% | -17.2% | +7.7% | +385.9% | -36.2% | +185.2% | +55.0% | -138.4% | +36.9% | -247.0% | -28.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 36.9% | 5.7% | 11.5% | 9.1% | 10.7% | 8.2% | 7.2% | 13.0% | 12.2% | -3.1% | 11.9% | -14.0% | 6.1% |
| — | -31.2% | +60.1% | -30.0% | -12.2% | +365.0% | -39.6% | +193.0% | +101.0% | -146.6% | +60.3% | -249.1% | -44.2% | |
| ROA | 14.4% | 2.2% | 4.7% | 3.8% | 4.4% | 3.2% | 2.7% | 5.0% | 4.5% | -1.1% | 4.5% | -5.6% | 2.6% |
| — | -30.3% | +70.7% | -23.8% | -2.4% | +377.7% | -38.9% | +188.7% | +72.3% | -141.2% | +48.2% | -252.6% | -35.9% | |
| ROIC | 22.0% | 5.6% | 7.4% | 6.3% | 6.9% | 4.7% | 4.3% | 6.6% | 6.3% | -1.9% | 6.4% | -5.5% | 4.3% |
| — | +20.7% | +70.8% | -4.4% | +8.6% | +344.9% | -32.5% | +221.2% | +48.2% | -147.1% | +34.2% | -192.9% | -34.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Merck & Co., Inc.'s Debt/EBITDA ratio is 5.9x, up from 4.8x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 12.6% YoY to 1.54x, strengthening the short-term liquidity position. Debt/Equity has risen for 4 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.96 | 0.96 | 0.80 | 0.72 | 0.72 | 0.83 | 0.86 | 0.87 | 0.85 | 0.96 | 0.84 | 0.95 | 0.66 |
| — | +16.3% | -6.9% | -16.6% | -15.0% | -14.4% | +1.4% | -9.1% | +29.1% | +38.8% | +23.5% | +30.3% | -15.6% | |
| Debt / EBITDA | 1.72 | 5.86 | 4.85 | 4.77 | 4.46 | 6.90 | 7.38 | 5.20 | 5.07 | — | 5.06 | — | 6.41 |
| — | -15.1% | -34.3% | -8.3% | -12.1% | — | +45.7% | — | -20.8% | — | -15.7% | — | +35.9% | |
| Current Ratio | 1.54 | 1.54 | 1.66 | 1.42 | 1.41 | 1.36 | 1.36 | 1.47 | 1.25 | 1.25 | 1.38 | 1.28 | 1.44 |
| — | +12.6% | +21.8% | -2.9% | +12.6% | +9.0% | -1.4% | +14.4% | -13.2% | -15.0% | -5.2% | -7.6% | +3.3% | |
| Quick Ratio | 1.30 | 1.30 | 1.44 | 1.17 | 1.16 | 1.15 | 1.15 | 1.22 | 0.99 | 1.00 | 1.12 | 1.03 | 1.19 |
| — | +13.2% | +24.5% | -3.9% | +17.2% | +14.4% | +3.1% | +18.5% | -16.6% | -18.3% | -8.0% | -10.4% | +4.6% | |
| Interest Coverage | 17.31 | 14.99 | 22.82 | 20.85 | 21.44 | 13.71 | 13.39 | 20.37 | 19.71 | -5.60 | 18.73 | -18.26 | 16.08 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying MRK stock.
Merck & Co., Inc.'s current P/E is 15.6x. The average P/E over the last 4 quarters is 13.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Merck & Co., Inc.'s current operating margin is 36.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Merck & Co., Inc.'s business trajectory between earnings reports.